Phase III trial of BIVV-009 for cold agglutinin disease
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2017
At a glance
- Drugs TNT 009 (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Therapeutic Use
- Sponsors Bioverativ
- 01 Nov 2017 According to a Bioverativ media release, the company plans to initiate this trial by the end of the year 2017.
- 30 Oct 2017 New trial record
- 26 Oct 2017 According to a Bioverative media release, the company expected to initiate this trial before the end of 2017.